Vivimed Labs Limited is facing increased regulatory scrutiny as its senior financial executives have come under the purview of a Central Bureau of Investigation inquiry. The pharmaceutical company's Chief Financial Officer and Company Secretary have received official notices from the CBI following formal complaints raised by one of India's largest public sector banks.

CBI Investigation Details

The Central Bureau of Investigation has issued notices to Vivimed Labs' Chief Financial Officer and Company Secretary as part of an ongoing investigation. The notices were served following a complaint filed by State Bank of India, which has raised concerns about financial irregularities involving the company.

Regulatory Implications

The involvement of the CBI in this matter indicates the serious nature of the financial issues that have been brought to light. When public sector banks file complaints with investigative agencies, it typically suggests significant concerns about financial compliance or potential irregularities that require detailed examination.

Company Impact

This development places Vivimed Labs under regulatory spotlight, with its key financial executives now required to respond to the CBI's inquiries. The pharmaceutical company will need to address the concerns raised by State Bank of India while cooperating with the ongoing investigation process.

Vivimed Labs Limited has announced that its Board of Directors will meet on February 13, 2026, to review and approve the company's third quarter financial results for FY26. The pharmaceutical company made this announcement in compliance with regulatory requirements, notifying both major stock exchanges about the scheduled board meeting.

Meeting Details and Agenda

The board meeting is scheduled to take place on Friday, February 13, 2026, at the company's Hyderabad office. The primary agenda includes consideration and approval of unaudited financial results covering both standalone and consolidated performance metrics.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015. Vivimed Labs communicated this information to both BSE Limited and National Stock Exchange of India Ltd, where the company's shares are traded under the codes BSE - 532660 and NSE - VIVIMEDLAB respectively.

Company Information

Vivimed Labs Limited operates with its registered office located at Kolhar Industrial Area, Bidar, Karnataka, while maintaining its corporate office in Hyderabad, Telangana. The company secretary Yugandhar Kopparthi signed the official communication to the stock exchanges. The meeting agenda also includes consideration of any other items that may be brought before the board during the session.

Investors and stakeholders will be awaiting the financial results that will provide insights into the company's performance for the quarter and nine months ending December 31, 2025.